Butaclamol hydrochloride (AY-23,028): an early evaluation in severely ill schizophrenics.

PubWeight™: 0.83‹?›

🔗 View Article (PMID 1089058)

Published in Dis Nerv Syst on January 01, 1975

Authors

D H Mielke, D M Gallant, T Oelsner, C M Kessler, W K Tomlinson, G H Cohen

Articles by these authors

(truncated to the top 100)

Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science (1998) 7.89

A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell (1999) 6.82

Type-common CP-1 antigen of herpes simplex virus is associated with a 59,000-molecular-weight envelope glycoprotein. J Virol (1978) 5.12

A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus. Virology (1998) 4.67

Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol Cell (2001) 4.44

Three classes of cell surface receptors for alphaherpesvirus entry. Virology (2000) 4.41

LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity (1998) 4.23

Phosphocholine binding immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A. J Mol Biol (1986) 4.16

A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med (1989) 4.04

Structural analysis of the capsid polypeptides of herpes simplex virus types 1 and 2. J Virol (1980) 3.95

Essential role of LAT in T cell development. Immunity (1999) 3.94

The three-dimensional structure of a phosphorylcholine-binding mouse immunoglobulin Fab and the nature of the antigen binding site. Proc Natl Acad Sci U S A (1974) 3.92

Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature (1984) 3.80

Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody. J Virol (1984) 3.53

Interactions of protein antigens with antibodies. Proc Natl Acad Sci U S A (1996) 3.53

X-ray fiber diffraction and model-building study of polyguanylic acid and polyinosinic acid. J Mol Biol (1975) 3.50

Three-dimensional structure of an antibody-antigen complex. Proc Natl Acad Sci U S A (1987) 3.48

Differentiation of T cells induced by preparations from thymus and by nonthymic agents. J Exp Med (1973) 3.12

Isolation of a herpes simplex virus-specific antigenic fraction which stimulates the production of neutralizing antibody. J Virol (1972) 3.11

Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. J Virol (1997) 3.05

Herpes simplex virus glycoprotein D can bind to poliovirus receptor-related protein 1 or herpesvirus entry mediator, two structurally unrelated mediators of virus entry. J Virol (1998) 3.00

Effect of tunicamycin on herpes simplex virus glycoproteins and infectious virus production. J Virol (1980) 2.99

Synthesis and processing of glycoproteins gD and gC of herpes simplex virus type 1. J Virol (1980) 2.94

Factor VIII:C inhibitor associated with monoclonal-antibody purified FVIII concentrate. Lancet (1990) 2.91

Localization of discontinuous epitopes of herpes simplex virus glycoprotein D: use of a nondenaturing ("native" gel) system of polyacrylamide gel electrophoresis coupled with Western blotting. J Virol (1986) 2.91

Localization of epitopes of herpes simplex virus type 1 glycoprotein D. J Virol (1985) 2.71

Purification of glycoprotein gD of herpes simplex virus types 1 and 2 by use of monoclonal antibody. J Virol (1982) 2.71

Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci U S A (1999) 2.69

Fine mapping of antigenic site II of herpes simplex virus glycoprotein D. J Virol (1989) 2.68

Comparative structural analysis of glycoprotein gD of herpes simplex virus types 1 and 2. J Virol (1980) 2.65

Structure of an antibody-antigen complex: crystal structure of the HyHEL-10 Fab-lysozyme complex. Proc Natl Acad Sci U S A (1989) 2.65

Effect of monoclonal antibodies on limited proteolysis of native glycoprotein gD of herpes simplex virus type 1. J Virol (1982) 2.62

Deoxyribonucleic acid synthesis in synchronized mammalian KB cells infected with herpes simplex virus. J Virol (1971) 2.25

Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J Virol (1995) 2.24

Ribonucleotide reductase activity of synchronized KB cells infected with herpes simplex virus. J Virol (1972) 2.23

Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. J Lab Clin Med (1992) 2.22

Oligomeric structure of glycoproteins in herpes simplex virus type 1. J Virol (1996) 2.22

Interactions of vesicular stomatitis virus structural proteins with HeLa plasma membranes. Nat New Biol (1971) 2.19

Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. Microb Pathog (1987) 2.15

Monoclonal antibodies to distinct sites on herpes simplex virus (HSV) glycoprotein D block HSV binding to HVEM. J Virol (1998) 2.11

Structural analysis of precursor and product forms of type-common envelope glycoprotein D (CP-1 antigen) of herpes simplex virus type 1. J Virol (1979) 2.10

Purification and properties of bovine thymosin. Ann N Y Acad Sci (1975) 2.08

Structure-function analysis of soluble forms of herpes simplex virus glycoprotein D. J Virol (1996) 2.05

The first immunoglobulin-like domain of HveC is sufficient to bind herpes simplex virus gD with full affinity, while the third domain is involved in oligomerization of HveC. J Virol (1999) 2.03

Examination of the kinetics of herpes simplex virus glycoprotein D binding to the herpesvirus entry mediator, using surface plasmon resonance. J Virol (1998) 2.02

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood (2001) 1.99

Localization of a binding site for herpes simplex virus glycoprotein D on herpesvirus entry mediator C by using antireceptor monoclonal antibodies. J Virol (2000) 1.98

High-level expression and purification of secreted forms of herpes simplex virus type 1 glycoprotein gD synthesized by baculovirus-infected insect cells. J Virol (1994) 1.97

The galactan-binding immunoglobulin Fab J539: an X-ray diffraction study at 2.6-A resolution. Proteins (1986) 1.96

Identification of functional regions of herpes simplex virus glycoprotein gD by using linker-insertion mutagenesis. J Virol (1994) 1.85

The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem (2000) 1.84

Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol (1994) 1.83

Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2. Infect Immun (1984) 1.83

The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia (2003) 1.80

Refined crystal structure of gamma-chymotrypsin at 1.9 A resolution. Comparison with other pancreatic serine proteases. J Mol Biol (1981) 1.80

Inhibition of herpes simplex virus type 2 replication by thymidine. J Virol (1974) 1.77

Antigenic analysis of a major neutralization site of herpes simplex virus glycoprotein D, using deletion mutants and monoclonal antibody-resistant mutants. J Virol (1988) 1.74

Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol (1986) 1.72

Functional region IV of glycoprotein D from herpes simplex virus modulates glycoprotein binding to the herpesvirus entry mediator. J Virol (1998) 1.70

Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization. J Infect Dis (1990) 1.69

Fine structure analysis of type-specific and type-common antigenic sites of herpes simplex virus glycoprotein D. J Virol (1984) 1.63

Acquired inhibitors. Baillieres Clin Haematol (1996) 1.62

Cross-linking of glycoprotein oligomers during herpes simplex virus type 1 entry. J Virol (1996) 1.62

D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62

Treatment of inherited coagulation disorders. Am J Med (1995) 1.60

Morphological components of herpesvirus. III. Localization of herpes simplex virus type 1 nucleocapsid polypeptides by immune electron microscopy. J Gen Virol (1981) 1.60

Separation of Herpes simplex virus-induced antigens by Concanavalin A affinity chromatography. J Virol (1973) 1.59

The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge. J Virol (1998) 1.57

The major neutralizing antigenic site on herpes simplex virus glycoprotein D overlaps a receptor-binding domain. J Virol (1999) 1.57

Glycopeptides of the type-common glycoprotein gD of herpes simplex virus types 1 and 2. J Virol (1983) 1.55

Structural and antigenic analysis of a truncated form of the herpes simplex virus glycoprotein gH-gL complex. J Virol (1998) 1.54

von Willebrand factor interacts with malignant hematopoietic cell lines: evidence for the presence of specific binding sites and modification of von Willebrand factor structure and function. J Lab Clin Med (1992) 1.54

Detection of a virus-specific antigen on the surface of herpes simplex virus-transformed cells. J Virol (1975) 1.52

Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge. J Virol (1985) 1.51

Porcine HveC, a member of the highly conserved HveC/nectin 1 family, is a functional alphaherpesvirus receptor. Virology (2001) 1.49

Antigenic and functional analysis of a neutralization site of HSV-1 glycoprotein D. Virology (1990) 1.49

Synthesis and processing of glycoprotein D of herpes simplex virus types 1 and 2 in an in vitro system. J Virol (1983) 1.48

PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost (1998) 1.48

Ribonucleotide reductase from herpes simplex virus (types 1 and 2) infected and uninfected KB cells: properties of the partially purified enzymes. J Gen Virol (1977) 1.47

Development of a syngenic murine B16 cell line-derived melanoma susceptible to destruction by neuroattenuated HSV-1. Mol Ther (2001) 1.47

Two distinct binding affinities of poliovirus for its cellular receptor. J Biol Chem (2000) 1.45

Structure and refinement at 1.8 A resolution of the aspartic proteinase from Rhizopus chinensis. J Mol Biol (1987) 1.43

Amino-terminal sequence of glycoprotein D of herpes simplex virus types 1 and 2. J Virol (1984) 1.42

B.C.E., or C.E., which? Pharos Alpha Omega Alpha Honor Med Soc (1998) 1.39

Influence of asparagine-linked oligosaccharides on antigenicity, processing, and cell surface expression of herpes simplex virus type 1 glycoprotein D. J Virol (1989) 1.38

Antigenic structure of soluble herpes simplex virus (HSV) glycoprotein D correlates with inhibition of HSV infection. J Virol (1997) 1.36

Disulfide bond structure of glycoprotein D of herpes simplex virus types 1 and 2. J Virol (1992) 1.36

Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. J Virol (1996) 1.36

Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med (1986) 1.32

Analysis of the intracellular maturation of the herpes simplex virus type 1 glycoprotein gH in infected and transfected cells. Virology (1991) 1.31

The contribution of cysteine residues to antigenicity and extent of processing of herpes simplex virus type 1 glycoprotein D. J Virol (1988) 1.27

HveA (herpesvirus entry mediator A), a coreceptor for herpes simplex virus entry, also participates in virus-induced cell fusion. J Virol (1998) 1.27

Morphological components of herpesvirus. I. Intercapsomeric fibrils and the geometry of the capsid. Intervirology (1974) 1.27

Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J Virol (1998) 1.26

Identification of a site on herpes simplex virus type 1 glycoprotein D that is essential for infectivity. J Virol (1990) 1.26

Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet (1988) 1.24

Structural basis of C3b binding by glycoprotein C of herpes simplex virus. J Virol (1992) 1.23

Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J Immunol (1997) 1.22

Use of chimeric nectin-1(HveC)-related receptors to demonstrate that ability to bind alphaherpesvirus gD is not necessarily sufficient for viral entry. Virology (2001) 1.21

Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia (2011) 1.21